References
- https://www.nice.org.uk/guidance/ng23, accessed 13.04.2016
- Baber RJ, Panay N, Fenton A, and the IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
- Khan K. The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health. Climacteric 2014;17:520–1
- Panay N, Fenton A. Has the time for the definitive, randomized, placebo-controlled HRT trial arrived? Climacteric 2011;14:195–6
- Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015;22:976–83
- https://poiregistry.net, accessed 13.04.2016
- Miller VM, Jenkins GD, Biernacka JM, et al. Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiol Genomics 2016;48:33–41
- Hodis HN, Mack WJ, Henderson VW, et al.; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31